Supportive module 1: “Essentials of diagnosis, treatment and prevention of major endocrine diseases”

| 5. | Diseases of the hypothalamic-pituitary system. Its part in correction of the functional activity of the endocrine glands. | 2 | 04/10 |
Essentials of Diagnosis, Treatment and Prevention of Major Endocrine Diseases:

LECTURE IN INTERNAL MEDICINE FOR IV COURSE STUDENTS

M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, N. Makienko
V.N. Karazin National University Medical School’ Internal Medicine Dept.
Plan of the Lecture

- Definition
- Epidemiology
- Risk factors
- Etiology
- Mechanisms
- Classification
- Clinical presentation
- Diagnosis
- Treatment
- Prognosis
- Prophylaxis
- Abbreviations
- Diagnostic guidelines
Definition

Diseases of the Hypothalamic-Pituitary System

• The hypothalamus and pituitary form a functionally integrated complex

• Damage to the hypothalamic-pituitary system can impact the responsiveness and normal functioning of the pituitary and may cause inhibited signalling to the pituitary and/or decreased functioning of the pituitary leading to deficiencies of one or more of the following hormones: thyroid-stimulating hormone (TSH), adrenocorticototropic hormone (ACTH), beta-endorphin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL) and melanocyte–stimulating hormones (MSH)

• Damage to the hypothalamic-pituitary system may too cause excess pituitary hormone secretion.

Epidemiology
Diseases of the Hypothalamic-Pituitary System

Bar graph showing the breakdown of disease distribution. Pituitary adenomas and craniopharyngiomas were the most common lesions encountered. The numbers on the y axis denote the number of patients with the disease. GH = growth hormone; TSH = thyroid-stimulating hormone.

Epidemiology
Diseases of the Hypothalamic-Pituitary System

A pie chart demonstrating the distribution by age of patients with pituitary tumors.
### Epidemiology

**Diseases of the Hypothalamic-Pituitary System**

<table>
<thead>
<tr>
<th>Diagnosis code</th>
<th>Diagnosis</th>
<th>No of cases sampled</th>
<th>No of cases examined</th>
<th>No of missing records</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25300</td>
<td>Acromegaly</td>
<td>59</td>
<td>53</td>
<td>6</td>
</tr>
<tr>
<td>25301</td>
<td>Pituitary gigantism</td>
<td>5</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>25302</td>
<td>Pituitary adenoma, eosinophilic</td>
<td>4</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>25308</td>
<td>Hyperpituitarism, other specified</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>25309</td>
<td>Hyperpituitarism, not specified</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>25329</td>
<td>Pituitary adenoma, chromophobe</td>
<td>36</td>
<td>29</td>
<td>7</td>
</tr>
<tr>
<td>25801</td>
<td>Pituitary adenoma, basophilic</td>
<td>5</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>19439</td>
<td>Malignant neoplasm of pituitary gland and craniopharyngeal duct</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>22620</td>
<td>Benign neoplasm of pituitary gland</td>
<td>26</td>
<td>21</td>
<td>5</td>
</tr>
<tr>
<td>22629</td>
<td>Benign neoplasm of pituitary gland and craniopharyngeal duct</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ICD-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E22.0</td>
<td>Acromegaly and pituitary gigantism</td>
<td>223</td>
<td>218</td>
<td>5</td>
</tr>
<tr>
<td>E22.1</td>
<td>Hyperprolactinaemia</td>
<td>578</td>
<td>116</td>
<td>4</td>
</tr>
<tr>
<td>E22.8</td>
<td>Other hyperfunction of pituitary gland</td>
<td>23</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>E22.9</td>
<td>Hyperfunction of pituitary gland, unspecified</td>
<td>28</td>
<td>27</td>
<td>1</td>
</tr>
<tr>
<td>C75.1</td>
<td>Malignant neoplasms, pituitary gland</td>
<td>4</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>D35.2</td>
<td>Benign neoplasm of other and unspecified endocrine glands, pituitary gland</td>
<td>460</td>
<td>93</td>
<td>5</td>
</tr>
<tr>
<td>D44.3</td>
<td>Neoplasm of uncertain or unknown behaviour of endocrine glands, pituitary gland</td>
<td>49</td>
<td>48</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>1504</td>
<td>647</td>
<td>37</td>
</tr>
</tbody>
</table>


https://www.dovepress.com/acromegaly-according-to-the-danish-national-registry-of-patients-how-v-peer-reviewed-fulltext-article-CLP
Risk Factors and Etiology
Diseases of the Hypothalamic-Pituitary System

- Anorexia
- Bleeding
- Bulimia
- Genetic disorders
- Growths (tumors)
- Head trauma
- Infections and swelling (inflammation)
- Malnutrition
- Radiation
- Surgery
- Hyperironemia

He Pingping from China and Sultan Kosen from Turkey.
Mechanisms
Hypothalamo-Anterior Pituitary Link

http://medical-dictionary.thefreedictionary.com/Hypopituitarism
Mechanisms
Diseases of the Hypothalamic-Pituitary System

Commonly hormone deficiencies may include:

• Gonadotropin deficiency involves LH and FSH affecting the reproductive system in men and women and menstruation in women
• TSH deficiency leads to hypothyroidism
• ACTH deficiency leads to a reduction in the secretion of adrenal hormones, resulting in hypoadrenalism
• GH deficiency has a variety of different negative effects at different ages (e.g., in newborn infants may be hypoglycemia or micropenis, while in later infancy and childhood growth failure is more likely)

http://medical-dictionary.thefreedictionary.com/Hypopituitarism
Mechanisms
Diseases of the Hypothalamic-Pituitary System

Other hormone deficiencies:
• PRL deficiency leads to diabetes insipidus

Multiple hormone deficiencies:
• Deficiency of a single pituitary hormone occurs less commonly than deficiency of more than one hormone
• Generally, GH is lost first, then LH deficiency follows
• The loss of FSH, TSH and ACTH follow much later
• The progressive loss of pituitary hormone secretion is usually a slow process, which can occur over a period of months or years

Panhypopituitarism (pituitary failure) represents the loss of all hormones released by the anterior pituitary gland.
Mechanisms
Diseases of the Hypothalamic-Pituitary System

Pituitary tumours may produce excess hormone, or they can block hormone production, or it can be ‘non-functioning’ (hormone production not affected in any way).

International Classification of Diseases

Chapter IV
(E00-E90) Endocrine, nutritional and metabolic diseases

E22 Hyperfunction of pituitary gland
E23 Hypofunction and other disorders of pituitary gland
  E23.0 Hypopituitarism
  E23.1 Drug-induced hypopituitarism
  E23.2 Diabetes insipidus
  E23.3 Hypothalamic dysfunction, not elsewhere classified
E23.6 Other disorders of pituitary gland
E23.7 Disorder of pituitary gland, unspecified
Clinical Classification

- Pituitary tumors (adenomas)
- Hypopituitarism
  - Somatotropin (GH) Deficiency
  - Gonadotropin Deficiency
  - Corticotropin Deficiency
  - Thyrotropin Deficiency
- Excess Pituitary Hormone Secretion
  - Prolactinomas
  - Acromegaly
  - Cushing’s Disease
  - Thyrotropin-Secreting Adenoma
- Nonfunctional and Glycoprotein-secreting Pituitary Adenomas
- Lymphocytic Hypophysitis
- Empty Sella
- Pituitary Apoplexy
- Diabetes Insipidus
Partial List of Signs and Symptoms

Tumor symptoms
• Headaches
• Loss of vision

Hypothyroidism symptoms
• Cold intolerance
• Constipation
• Depressed mood
• Fatigue
• Hair or skin changes
• Hoarseness
• Impotence
• Loss of body hair and muscle (in men)
• Mental slowing
• Menstrual cycle changes
• Weight gain

Low adrenal function symptoms
• Dizziness
• Weakness

Other symptoms
• Body temperature problems
• Emotional problems
• Excess thirst
• Obesity
• Uncontrolled urination
• Kallmann's syndrome (a type of hypothalamic dysfunction that occurs in men) symptoms:
  • Lowered function of sexual hormones (hypogonadism)
  • Inability to smell

Partial List of Signs and Symptoms

Symptoms of PITUITARY CONDITIONS may include...

- Facial changes
- Joint pain
- Fatigue
- Depression
- Growth failure in children
- Irregular periods
- Blood pressure
- Excess urination
- Large hands & feet
- Vision impairment
- Weight gain or loss
- Nipple secretion
- Loss of libido
- Sleep disturbance

http://cephalicvein.com/2016/07/pituitary-tumor-symptoms/
Partial List of Signs and Symptoms

- Vomiting
- Mood Swings
- Cognitive Decline
- Hearing Problems
- Headache
- Speech Problems
- Seizures
Pituitary Tumors

Etiology

- Pituitary adenomas (microadenomas <10 mm, macroadenomas ≥10 mm) arise from adenohypophyseal cells and are almost always benign.
- Pituitary adenomas discovered by computed tomography (CT) or magnetic resonance imaging (MRI) examination, in the absence of any symptoms or clinical findings, are referred to as pituitary incidentalomas.
- Pituitary adenomas are rarely associated with parathyroid and neuroendocrine hyperplasia or neoplasia as part of the multiple endocrine neoplasia type I (MEN I) syndrome.
- Pituitary carcinomas are extremely rare, but metastases from other solid malignancies (mainly breast and lung) can occur.
Pituitary Tumors
Signs and Symptoms

• Pituitary tumors can manifest with signs and symptoms of pituitary hypofunction, hormone hypersecretion, or mass effect
• Impingement on the chiasma by a pituitary tumor results in visual field defects, most commonly bitemporal hemianopia
• Patients with sellar mass pressing on the optic chiasma should have a Humphrey visual field test
• Lateral extension of the pituitary mass to the cavernous sinuses can result in diplopia, ptosis, or altered facial sensation
• There is no specific headache pattern associated with pituitary tumors and, in some patients, the headache is unrelated to pituitary adenoma.
Impingement on the chiasma by a pituitary tumor results in visual field defects, most commonly bitemporal hemianopia.
Pituitary Tumors
Diagnosis and Treatment

• Magnetic resonance imaging (MRI) is the best method for the visualizing hypothalamic-pituitary anatomy
• Once a pituitary adenoma is found, it is necessary to determine its type (secretory vs. nonsecretory), pituitary function, and whether there is any visual field defect
• The treatment include reduction or complete removal of the tumor, elimination of mass effect, normalization of hormone hypersecretion, and restoration of normal pituitary function
• Some patients with large tumors require additional medical, and radiation therapies
• The most important factor in pituitary surgery is the availability of an experienced neurosurgeon.

clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/pituitary-disorders/
Large non-functioning pituitary adenoma disclosed in a patient with macroprolactinemia (arrows).
Hypopituitarism
Etiology

- Pituitary adenomas are the most common cause of hypopituitarism, but other causes include parasellar diseases, pituitary surgery, radiation therapy, inflammatory and granulomatous diseases, and head injury.
- The sequential loss of pituitary hormones secondary to a mass effect is in the following order: GH, LH, FSH, TSH, ACTH, and prolactin.
- Isolated deficiencies of various anterior pituitary hormones can occur.
- In general, pituitary microadenomas are rarely associated with hypopituitarism.
- Diabetes insipidus is almost never seen in patients with pituitary adenomas at presentation.
Hypopituitarism
Somatotropin (GH) Deficiency

• GP deficiency in premenopausal women is recognized early on account of amenorrhea, infertility or loss of libido
• Men often delay presentation on developing impotence or loss of libido, though with wider recognition of effective management of erectile dysfunction this pattern is reversing, provided other practitioners check for hormonal causes
• Patients with GH deficiency have increased body fat and decreased lean body mass, and they might have decreased bone mineral density
• GH deficiency is evaluated by dynamic testing, including the insulin tolerance test or GH-releasing hormone (RH)/arginine test
• Adult GH deficiency is diagnostically valuable and clinically important, since recombinant GH therapy is available.
Hypopituitarism
Somatotropin (GH) Deficiency

© 2006 Encyclopædia Britannica, Inc
https://media1.britannica.com/eb-media/13/93313-004-70936098.jpg
Hypopituitarism
Somatotropin (GH) Deficiency
Hypopituitarism

Gonadotropin Deficiency or Hypogonadism

- In women, hypogonadism causes infertility and oligomenorrhea or amenorrhea often associated with lack of libido, hot flushes, and dyspareunia
- In men, hypogonadism is diagnosed less often, because decreased libido and impotence may be considered functions of aging
- Osteopenia is a consequence of long-standing hypogonadism and responds to hormone replacement therapy
- Hypogonadism is diagnosed in the presence of low or normal LH and FSH levels in women, or in men with testosterone levels <200 ng/dL
- Estrogen replacement is necessary in women to prevent osteoporosis and to treat hot flushes, decreased libido, and vaginal dryness
- Testosterone in man may be replaced by intramuscular injection, transdermal patch, or a gel (oral testosterone is not recommended).
Hypopituitarism
Gonadotropin Deficiency or Hypogonadism
Hypopituitarism
Corticotropin (ACTH) Deficiency

- Patients with ACTH deficiency maintain mineralocorticoid secretion because aldosterone is regulated primarily by the renin-angiotensin system and serum potassium concentration.
- Symptoms include chronic malaise, fatigue, anorexia, low-grade fever, hypoglycemia, and less often hyponatremia.
- An ACTH stimulation test and early morning (8 am) plasma cortisol level measurement are initial tests: cortisol level <3 μg/dL confirms adrenal insufficiency, a level >15 μg/dL makes the diagnosis unlikely, and a levels in the intermediate range demands additional cosynaptropin stimulation test (CST).
- Hydrocortisone replacement is necessary in doses (15 – 20) mg/day, with the highest one given in the morning.
- In case of an acute distress patients should be instructed to carry a medical alert, and double replacement dosage for 2 to 3 days.
Hypopituitarism
Thyrotropin (TSH) Deficiency

- TSH deficiency are similar to those in patients with primary hypothyroidism, including malaise, fatigue, leg cramps, dry skin, and cold intolerance.
- The diagnosis cannot be established only through measurement of TSH because these patients might have a normal TSH level.
- If secondary hypothyroidism is clinically suspected, TSH and free thyroxine ($T_4$) should be measured together: usually, patients have a low or normal TSH level along with a low free $T_4$ level.
- Therapy for TSH deficiency is similar to that for primary hypothyroidism.
- The levothyroxine replacement dose should be adjusted according to the patient’s clinical status and free $T_4$ and free triiodothyronine ($T_3$) levels, but not TSH.
Hypopituitarism
Thyrotropin (TSH) Deficiency

If TSH deficiency (secondary hypothyroidism) is clinically suspected, TSH and free thyroxine ($T_4$) should be measured together: usually, patients have a low or normal TSH level along with a low free $T_4$ level.
Excess Pituitary Hormone Secretion

Prolactinomas: Clinical Features

• Prolactinomas are pituitary adenomas that secrete PRL in varying degrees and account for about 30% of all pituitary adenomas
• Prolactinomas are more common in women, with a peak incidence during the childbearing years
• Clinical features related to excess prolactin
• Women of reproductive age mainly present with oligomenorrhea, amenorrhea, galactorrhea, or infertility
• Men and postmenopausal women usually come to medical attention because of mass effect, such as headaches and visual field defects
• The majority of patients with a serum PRL level >100 μg/L have prolactinoma
• A serum PRL level <100 μg/L in the presence of a large pituitary adenoma suggests stalk compression.
Microprolactinoma in a patient with primary hypothyroidism (arrow). This condition should be considered whenever PRL levels remain elevated following normalization of TSH and free $T_4$. 

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000100009
Microprolactinoma in a patient with macroprolactinemia (arrow). After PEG precipitation, PRL recovery was low (25%) but PRL levels remained elevated (93 ng/mL).
Giant invasive pituitary prolactinoma with falsely low serum PRL (103 ng/mL.) due to the hook effect. PRL levels rose to 13,144 ng/mL after a 1:100 serum sample dilution (Adapted from Ref. 89).
Excess Pituitary Hormone Secretion
Prolactinomas: Diagnosis

Diffuse pituitary enlargement in a patient with primary hypothyroidism-induced hyperprolactinemia, before (A) and after (B) L-thyroxine replacement.
Excess Pituitary Hormone Secretion
Prolactinomas: Treatment

• Dopamine agonists are the therapy of choice for most patients, and they are effective in decreasing adenoma size and restoring normal PRL level in most patients; the most common side effects include nausea, headache, dizziness, nasal congestion, and constipation.

• Cabergoline and bromocriptine are potent inhibitors of PRL secretion and often cause tumor shrinkage; cabergoline is more potent, may be taken only twice a week, and is better tolerated by most patients.

• Surgery is reserved for patients who are intolerant of or refractory to medical therapy.

• Radiation therapy may be considered for patients who poorly tolerate dopamine agonists and cannot be cured by surgery.
Acromegaly: Clinical Features

• Acromegaly is a rare disease caused by a GH-secreting pituitary adenoma in more than 99% of patients.

• Excess GH before the fusion of the epiphyseal growth plates results in gigantism.

• Clinical features include arthralgias, neuropathic, carpal tunnel syndrome, coarsening of facial features, excessive sweating, goiter, hypertension, heart failure, arrhythmias, impaired glucose tolerance, macroglossia, tooth gaps, pituitary mass effect and insufficiency, sensory and motor peripheral neuropathies, sleep apnea, etc.

• Acromegalic patients carry an increased risk of malignancy such as premalignant adenomatous colon polyps and colon cancer.

• Random GH levels are associated with increased morbidity and mortality if untreated.
Excess Pituitary Hormone Secretion

Acromegaly: Clinical Features

- The most commonly noticed symptom is abnormal enlargement of the hands and feet. Enlargement of the feet may require increasingly larger shoe size.
- Changes in facial features can include enlargement of forehead and jaw with pronounced under bite, spreading teeth and enlarging tongue. The nose and lips may enlarge as well.
Excess Pituitary Hormone Secretion

Acromegaly: Treatment

• The goal of therapy for most patients is to achieve a normal sex- and age-adjusted IGF-1 and GH less than 2 ng/mL
• Surgery is the treatment of choice even if a cure cannot be achieved
• Even a subtotal resection of the tumor will improve the efficacy of subsequent adjuvant therapy
• Somatostatin analogues inhibit GH secretion mainly by binding to somatostatin receptors and result in normalization of IGF-1 in up to 65% of patients
• Pegvisomant has higher affinity to GH receptors than native GH but inhibits its dimerization, which is necessary for the action of GH
• Dopamine agonists have variable efficacy but may be an attractive first-line therapy, especially in those with cosecretion of prolactin and GH.
Excess Pituitary Hormone Secretion

Cushing’s Disease: Symptoms

• Cushing’s disease (CD) comprises symptoms and signs associated with prolonged exposure to inappropriately high levels of plasma ACTH-dependent free glucocorticoids

• The striae in CS are usually red-purple, more than 1 cm wide, and located on the abdomen, upper thighs, breasts, and arms

• Increased skin pigmentation is rare and only occurs in the ectopic ACTH syndrome

• Supraclavicular and dorsocervical fat pads (buffalo hump) and moon face are nonspecific and are seen in many patients of obesity clinics

• Women complain of menstrual irregularity (84%) and hirsutism (especially vellous hypertrichosis of the face), and men and women exhibit loss of libido (≤100%)

• Psychiatric abnormalities occur in 50% of patients.
### Excess Pituitary Hormone Secretion

#### Cushing’s Disease: Clinical Features

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central obesity</td>
</tr>
<tr>
<td>Unexplained osteoporosis</td>
</tr>
<tr>
<td>Proximal myopathy</td>
</tr>
<tr>
<td>Wide purplish striae (&gt;1 cm)</td>
</tr>
<tr>
<td>Facial plethora</td>
</tr>
<tr>
<td>Spontaneous bruising</td>
</tr>
<tr>
<td>Hypokalemia</td>
</tr>
<tr>
<td>Serial photographs</td>
</tr>
</tbody>
</table>

## Excess Pituitary Hormone Secretion

### Cushing’s Disease: Endogenous Causes

<table>
<thead>
<tr>
<th>ACTH-Dependent Cushing’s Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cushing’s disease (67%)</td>
</tr>
<tr>
<td>Ectopic ACTH secretion (12%)</td>
</tr>
<tr>
<td>Ectopic CRH secretion (&lt;1%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACTH-Independent Cushing’s Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal adenoma (10%)</td>
</tr>
<tr>
<td>Adrenal carcinoma (8%)</td>
</tr>
<tr>
<td>Micro- and macronodular adrenal hyperplasia (1%)</td>
</tr>
</tbody>
</table>
Excess Pituitary Hormone Secretion

Cushing’s Disease: Endogenous Causes

Red purplish abdominal striae 1 cm in width in a patient with CD
Excess Pituitary Hormone Secretion

Cushing’s Disease: Endogenous Causes
Excess Pituitary Hormone Secretion

Cushing’s Disease: Differential Diagnosis

[Flowchart diagram showing the diagnostic process for Cushing's syndrome and Cushing's disease.]

- Perform CRH stimulation test
  - Normal/equivocal: Measure plasma ACTH
    - High: Perform pituitary MRI
      - Positive: Cushing’s disease
        - Perform bilateral inferior petrosal sinus sampling
          - Positive: Search for ectopic ACTH source
          - Negative: Search for ectopic ACTH source
      - Normal/equivocal: ACTH independent Cushing’s syndrome
        - Perform adrenal CT or MRI
Excess Pituitary Hormone Secretion

Cushing’s Disease: Treatment

- Surgical removal of the ACTH-secreting pituitary tumor is the treatment of choice
- Availability of an experienced neurosurgeon is crucial, and the long-term remission rate is about 60 to 80% following surgery
- A low (<3 μg/dL) or undetectable postoperative cortisol level off glucocorticoids is considered to be a good marker for long-term cure
- Other options include reoperation and radiotherapy
- Bilateral adrenalectomy is reserved for those who continue to be hypercortisolemic
- Medical therapy (ketoconazole) has limited value because of the associated toxicity and gradual decrease in efficacy
- During therapy, liver function tests need to be closely monitored.
Excess Pituitary Hormone Secretion

Thyrotropin-Secreting Adenoma

- TSH-secreting pituitary adenomas account for <1% of all pituitary tumors at mean age 40 years, with a slight female predominance
- Symptoms secondary to hyperthyroidism and goiter are the initial complaints, if the disease remains undiagnosed
- The most important feature is elevation of serum $T_4$ and $T_3$ levels, with an inappropriately normal or elevated TSH level
- In patients with TSH-secreting adenomas, surgery is the primary therapeutic approach
- Radiation is generally used for those with residual tumor
- Somatostatin analogues are effective for control of excess TSH production leading possibly to a decrease in tumor size
- Beta blockers should be initiated in uncontrolled hyperthyroidism
- Antithyroid medications may be used only shortly before surgery.
Nonfunctional and Glycoprotein-Secreting Pituitary Adenomas

• Nonfunctional and glycoprotein-secreting pituitary tumors account for about 25% to 30% of all pituitary adenomas
• Many clinically nonfunctional pituitary adenomas are glycoprotein-producing tumors and usually manifest with clinical features related to mass effect, including visual field defect, hypopituitarism, and headache
• The standard treatment for patients with mass effect is surgery, mainly through the trans-sphenoidal approach
• Radiotherapy is indicated in patients with residual pituitary tumor following surgical debulking or in those who are not surgical candidates
• The use of high-dose dopamine agonists has been associated with a decrease in tumor size in only about 10% of patients.
Lymphocytic Hypophysitis

- Lymphocytic hypophysitis is a rare autoimmune inflammatory lesion of the pituitary gland, commonly affecting young women during late pregnancy or in the postpartum period.
- Lymphocytic hypophysitis is associated with other autoimmune disorders, mainly Hashimoto’s thyroiditis and Addison’s disease.
- The clinical manifestations relate to mass effect or hypopituitarism.
- The corticotropin axis is the most commonly affected axis.
- The chronologic association with pregnancy or the postpartum period and isolated ACTH deficiency is a diagnostic clue.
- Trans-sphenoidal surgery is the therapy of choice for patients with pituitary mass effect.
- It is important to monitor patients with varying degrees of hypopituitarism, because some have recovery of their pituitary axes.
Empty Sella

• The empty sella is defined as a sella that, regardless of its size, is completely or partly filled with cerebrospinal fluid
• An empty sella of normal size is a common incidental autopsy finding
• An empty sella is called secondary when it is seen after surgery, irradiation, or medical treatment for a pituitary pathology
• Most patients have no pituitary dysfunction, but partial or complete pituitary insufficiency has been reported
• The discovery of an empty sella needs to be followed by an endocrine evaluation to determine whether there is any associated pituitary dysfunction
• Management usually involves reassurance and hormone replacement, if necessary.
Empty Sella

The empty sella is defined as a sella that, regardless of its size, is completely or partly filled with cerebrospinal fluid.
Pituitary Apoplexy

- Pituitary apoplexy is a rare endocrine emergency resulting from hemorrhagic infarction of a preexisting pituitary tumor.
- The clinical manifestations are related to rapid expansion of the tumor secondary to hemorrhage, with compression of the pituitary gland and the perisellar structures leading to headache, hypopituitarism, visual field defect, and cranial nerve palsies.
- Headache is the most prominent symptom in most patients with clinically evident pituitary apoplexy.
- Once pituitary apoplexy is suspected, stress-dose glucocorticoids (e.g., dexamethasone 4 mg every 8 hours IV) should be initiated and pituitary MRI should be performed.
- Patients with mass effect benefit from tumor and blood clot debulking, which leads to resolution of visual field defects and improvement of cranial nerve palsies in most patients.
Pituitary apoplexy is a rare endocrine emergency resulting from hemorrhagic infarction of a preexisting pituitary tumor.

http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/pituitary-disorders/images/PituitaryDisordersfig8_large.jpg
Diabetes Insipidus
Types and Clinics

- Diabetes insipidus (DI) is characterized by the chronic excretion of abnormally large volumes (>50 mL/kg) of dilute urine.
- DI is usually underdiagnosed because the symptoms and signs are benign and many patients ignore them or are unaware of them.
- There are four major types of DI: central (neurogenic) DI, nephrogenic DI, primary polydipsia, and gestational DI.
- Central DI is secondary to inadequate ADH secretion.
- DI results in few symptoms, including polydipsia and polyuria.
- Nocturia of a large urine volume is often the primary reason for which patients seek medical attention.
- DI is not associated with any abnormality on the physical examination or routine laboratory evaluation, except a low urine osmolality.
Diabetes Insipidus

Diagnosis

• Once DM and hypercalcemia have been excluded, patients should have 24-hour urinary volume measured during ad libitum fluid intake

• DI is diagnosed in those with urinary output >50 mL/kg/day, urinary osmolality <300 mOsm/kg, and creatinine excretion 14-18 mg/kg body weight as an indicator of an accurate 24-hour urine collection

• Measurement of spot urine osmolality is unreliable to exclude or diagnose DI, because it may be decreased significantly in an otherwise healthy person who drinks large amounts of water

• Patients with DI who are conscious usually have sufficient thirst to maintain a normal serum sodium level in spite of polyuria

• Once the diagnosis has been established, the next step is to differentiate the type of DI

• A water deprivation test may need to be performed by an experienced endocrinologist to differentiate among types of partial DI.
# Diabetes Insipidus

## Involved Systems and Mechanisms

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Urine Osmolality (mOsm/kg)</th>
<th>After fluid deprivation</th>
<th>After desmopressin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurogenic DI</td>
<td>&lt;300</td>
<td></td>
<td>&gt;800</td>
</tr>
<tr>
<td>Nephrogenic DI</td>
<td>&lt;300</td>
<td></td>
<td>&lt;300</td>
</tr>
<tr>
<td>Primary Polydipsia</td>
<td>&gt;800</td>
<td></td>
<td>&gt;800</td>
</tr>
<tr>
<td>Partial DI or Polydipsia</td>
<td>300-800</td>
<td></td>
<td>&lt;800</td>
</tr>
</tbody>
</table>

There are four major types of DI: central (neurogenic) DI, nephrogenic DI, primary polydipsia, and gestational DI.
Correlation of plasma arginine vasopressin (AVP) with plasma osmolality in normal subjects, in patients who have central (pituitary) diabetes insipidus, and in those who have nephrogenic diabetes insipidus.
Diabetes Insipidus
Therapy

• The treatment of choice for central diabetes insipidus is intranasal synthetic replacement for vasopressin (desmopressin acetate) at doses of 5 to 20 mcg daily
• Central diabetes insipidus has responded to chlorpropamide with a 25% to 75% reduction in polyuria
• Oral repletion of water often is sufficient to reverse acute dehydration in diabetes insipidus
• There are no effective pharmacologic agents to treat a compulsive water drinker
• A low-osmolar, low-sodium diet should be initiated to manage congenital nephrogenic diabetes insipidus.
Diabetes Insipidus

Therapy

- The therapy of choice for central DI is the administration of the ADH analogue desmopressin (DDAVP)
- It is available in a subcutaneous form or as an oral or nasal spray
- The spray or oral form of desmopressin is usually started at bedtime and is gradually titrated for the desired antidiuretic effect.
Prognosis and Prophylaxis

- Many causes of hypothalamic dysfunction are treatable
- Most of the time missing hormones can be replaced.

Abbreviations

ACTH - adrenocorticotropic hormone
CD - Cushing’s disease
CST - cosyntropin stimulation test
FSH - follicle-stimulating hormone
GH - growth hormone
LH - luteinizing hormone
MRI - magnetic resonance imaging
MSH - melanocyte-stimulating hormones
AVP - plasma arginine vasopressin
RH - releasing hormone
TSH – thyroid stimulating hormone (TSH)
PEG - polyethylene glycol
PRL - prolactin
Diagnostic and Treatment Guidelines

• Hypothalamic and anterior pituitary disorders
• Hypothalamic-pituitary dysfunction
• Hypothyroidism
• Hyperthyroidism
• AANS - The pituitary gland and pituitary tumors
• Endocrine testing protocols: hypothalamic pituitary adrenal axis
• And management
• Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients
• Glucocorticoid Replacement in Pituitary Surgery: Guidelines for Perioperative Assessment